Drugs / Methylene Blue
Methylene Blue
also known as
Methylene Blue MMX · methylthioninium chloride · MB-MMX · TRx0014 · Basic blue 9 · Basic blue 9 trihydrate · C.I. 52015 · C.i. basic blue 9 · +22 more
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed methemoglobin reductase deficiency 1 milestone | |||||
| Filed | Japan (PMDA) | — | methemoglobin reductase deficiency | 2014-03-17 | “announced today that it has filed an NDA for the manufacture and marketing in Japan of the methaemoglobinaemia injection Methylene Blue” daiichisankyo.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansion | US (FDA) | PROVAYBLUE | — | 2024-01-08 | fda.gov ↗ |
| Approved | US (FDA) | PROVAYBLUE | — | 2016-04-08 | fda.gov ↗ |
| Approved | EU (EMA) | Methylthioninium chloride Proveblue | — | 2011-05-06 | europa.eu ↗ |
Trials 78 · started per year
today
EU approved 2011
US approved 2016
1
2
2
1
1
4
3
2
7
4
3
7
8
6
2
4
6
9
6
2004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT07494773 | Jun 2026 → May 2028 expected | skin infection | University of Oklahoma | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07435415 | Aug 2025 → Dec 2026 expected | head and neck cancer | China Medical University Hospital | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05850611 | Apr → Aug 2023 | ulcer of lower limbs | Mashhad University of Medical Sciences | Unknown | No outcome recorded |
| Phase 0 | NCT05232357 | Mar → May 2022 | digestive system neoplasm | Affiliated Hospital to Academy of Military Medical Sciences | Unknown | No outcome recorded |
| Phase 0 | NCT01836094 | Aug 2013 → Mar 2016 | — | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT07169487 | Jun 2025 → Jun 2028 expected | CADINS disease, cytokine release syndrome | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 1 | NCT04619290 | Oct → Nov 2020 | COVID-19 | Hospital Reg. Lic. Adolfo Lopez Mateos | Unknown | No outcome recorded |
| Phase 1 | NCT04933864 | Apr → May 2020 | COVID-19 | I.M. Sechenov First Moscow State Medical University | Completed | No outcome recorded |
| Phase 1 | NCT04370288 | Apr → Sep 2020 | COVID-19 | Mashhad University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1 | NCT04109859 | Apr 2019 → Jan 2021 | obstructive jaundice | Jiaolin Ning,MD | Unknown | No outcome recorded |
| Phase 1 | NCT02240498 | Sep 2014 → Sep 2023 | abscess | University of Rochester | Completed | No outcome recorded |
| Phase 1 | NCT01668433 | Jul 2013 → Oct 2014 | G6PD deficiency | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT02478281 | Oct 2012 | hereditary methemoglobinemia | American Regent, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05003492 | Sep → Oct 2021 | COVID-19 | Amr kamel khalil Ahmed | Unknown | No outcome recorded |
| Phase 221 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT06052956 | Jul 2026 → Jun 2031 expected | abscess | University of Rochester | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07179003 | Apr 2026 → Mar 2031 expected | breast abscess | University of Rochester | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07833319 | Nov 2025 → Jul 2027 expected | rectal cancer | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06887036 | Sep 2025 → Oct 2026 expected | chronic hepatitis B virus infection | Fondazione Epatocentro Ticino | Recruiting | No outcome recorded |
| Phase 2 | NCT05090657 | Feb → Aug 2022 | nosocomial infection | Ondine Biomedical Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05004805 | Aug → Dec 2021 | COVID-19 | Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences | Completed | No outcome recorded |
| Phase 2 | NCT07212842 | Apr 2021 → Aug 2023 | aortic valve disorder, cardiac valvular defect | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2 | NCT04354012 | Feb 2021 → Aug 2024 | hidradenitis suppurativa | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04635605 | Nov 2020 → Aug 2021 | COVID-19 | Fondazione Epatocentro Ticino | Completed | No outcome recorded |
| Phase 2 | NCT04376788 | May → Jul 2020 | COVID-19 | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT04089072 | Dec 2019 → Oct 2024 | infectious disease with sepsis | Carilion Clinic | Unknown | No outcome recorded |
| Phase 2 | NCT03446599 | Nov 2019 → May 2020 | coronary artery disorder, heart valve disorder, hypotensive disorder | Dartmouth-Hitchcock Medical Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03469284 | Feb 2019 → Feb 2022 | cancer, oral sensibility, disturbance of, stomatitis | M.D. Anderson Cancer Center | Completed | Met primary |
| Phase 2 | NCT02851108 | Oct → Dec 2016 | Plasmodium falciparum malaria | Heidelberg University | Completed | Missed primary |
| Phase 2 | NCT02831023 | Jul 2016 → Jan 2017 | malaria | University of California, San Francisco | Completed | Met primary |
| Phase 2 | NCT03177070 | May 2016 → May 2017 | ureteral disorder | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT02380573 | Jul 2015 → Apr 2022 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 2 | NCT02555488 | Jan → Oct 2015 | periapical periodontitis | Shahid Beheshti University | Unknown | No outcome recorded |
| Phase 2 | NCT01188694 | Sep 2009 → Apr 2013 | post-traumatic stress disorder | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00354380 | Sep → Nov 2006 | malaria | Heidelberg University | Completed | No outcome recorded |
| Phase 2 | NCT00784849 | Nov 2004 → Jun 2011 | breast cancer | Louisiana State University Health Sciences Center in New Orleans | Completed | No outcome recorded |
| Phase 2/33 trials · 1 met primary | ||||||
| Phase 2/3 | NCT07264543 | Jan → Nov 2026 expected | brain hypoxia - ischemia, infectious disease with sepsis | Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06306001 | Mar 2024 → Mar 2026 overdue | neonatal sepsis | Post Graduate Institute of Medical Education and Research, Chandigarh | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT04446871 | Mar 2017 → Dec 2020 | infectious disease with sepsis | Hospital Civil de Guadalajara | Completed | Met primary |
| Phase 311 trials | ||||||
| Phase 3 | NCT07311057 | Dec 2025 → Jan 2026 overdue | skin squamous cell carcinoma | Daryoush Hamidi Alamdari, PhD | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT07311070 | Oct 2025 → Jan 2026 overdue | morpheaform basal cell carcinoma, nodular basal cell carcinoma, skin infiltrative basal cell carcinoma | Daryoush Hamidi Alamdari, PhD | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06900140 | Jun 2025 → Mar 2026 | infectious disease with sepsis | Dr. Shannon M. Fernando | Completed | No outcome recorded |
| Phase 3 | NCT06702878 | Dec 2024 → Apr 2026 | infectious disease | Ondine Biomedical Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06660680 | Oct 2024 → Oct 2025 overdue | hemorrhoid | The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06532240 | Aug 2024 → Oct 2025 | infectious disease with sepsis | Northern Jiangsu People's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04295993 | Mar → Sep 2020 | infectious disease with sepsis | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT03038503 | Dec 2016 → Dec 2018 | infectious disease with sepsis | Ramathibodi Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01657448 | Jun → Nov 2016 | urethral syndrome | EMS | Completed | No outcome recorded |
| Phase 3 | NCT01797978 | Feb 2013 → Jan 2016 | infectious disease with sepsis | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00214877 | Nov 2003 → Oct 2007 | bipolar disorder | Nova Scotia Health Authority | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT07835932 | Oct 2026 → Oct 2028 expected | — | Chinese University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07861815 | Oct 2026 → Oct 2027 expected | colorectal cancer, ureteral disorder | Chinese University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07164807 | Aug 2025 → Aug 2026 overdue | hemorrhoid | The Affiliated Hospital of Putian University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04187053 | Feb 2020 → Dec 2022 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT03395223 | Jul 2018 → Aug 2020 | methemoglobinemia | Provepharm SAS | Completed | No outcome recorded |
| Phase 4 | NCT03120637 | Jan 2017 → Jan 2018 | cirrhosis of liver, infectious disease with sepsis, vascular disorder | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| Phase not applicable23 trials · 1 met primary | ||||||
| — | NCT06834087 | Mar → Sep 2025 | hyperpigmentation of the skin | Roaa Hadi Hussein Jasem | Completed | No outcome recorded |
| — | NCT06481410 | Jun 2024 → Jun 2026 | infectious disease with sepsis | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| — | NCT06520306 | Mar → Aug 2024 overdue | disease of bone structure | Wang wanxia | Enrolling by invitation | No outcome recorded |
| — | NCT06284941 | Jun 2023 → Feb 2024 | disease of bone structure | Wang wanxia | Completed | Met primary |
| — | NCT05830630 | May 2023 → Feb 2027 expected | — | Tanta University | Recruiting | No outcome recorded |
| — | NCT05664087 | Feb → Nov 2023 | periodontitis | The Dental Hospital of Zhejiang University School of Medicine | Completed | No outcome recorded |
| — | NCT04970602 | Jun 2021 → Jun 2023 | infectious disease with sepsis | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| — | NCT04529265 | May 2021 → Apr 2023 | delirium | Fudan University | Completed | No outcome recorded |
| — | NCT07866833 | Jun 2020 → Aug 2025 | psychotic disorder | King's College London | Completed | No outcome recorded |
| — | NCT03576105 | Dec 2019 → Apr 2024 | pericoronitis | University of Nove de Julho | Unknown | No outcome recorded |
| — | NCT03222544 | Apr 2019 → Apr 2020 | ulcer of lower limbs | Chongqing Medical University | Unknown | No outcome recorded |
| — | NCT04341844 | Jan 2019 → Apr 2020 | delirium | Fudan University | Completed | No outcome recorded |
| — | NCT04056923 | Jan → Jun 2018 | lung cancer, pulmonary coin lesion | Wen-zhao ZHONG | Completed | No outcome recorded |
| — | NCT03386201 | Jan → Jun 2018 | bile duct disorder | University of Oxford | Unknown | No outcome recorded |
| — | NCT03579979 | Aug 2017 → Aug 2019 | breast cancer | Chinese Academy of Sciences | Completed | No outcome recorded |
| — | NCT03406676 | Aug 2017 → Oct 2018 | obstructive jaundice | Southwest Hospital, China | Unknown | No outcome recorded |
| — | NCT03262077 | Oct 2016 → Jun 2017 | chronic periodontitis | University of Nove de Julho | Completed | No outcome recorded |
| — | NCT03049345 | Jul 2016 → Jun 2022 | gastric cancer | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| — | NCT02057393 | Jun 2014 → Jan 2016 | melanoma | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| — | NCT02084784 | Jan 2014 → Sep 2015 | breast cancer, lymph node adenoid cystic carcinoma | Chinese Academy of Sciences | Completed | No outcome recorded |
| — | NCT02938988 | Oct 2013 → Oct 2016 | periodontitis | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT00314405 | Apr 2006 → Apr 2007 | invasive breast carcinoma | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| — | NCT00070317 | Jun 2004 → Jan 2013 | cervical adenosquamous carcinoma | Gynecologic Oncology Group | Terminated | No outcome recorded |
| Comparator or background therapy25 trials | ||||||
| Phase 1 | NCT07324954 Background | Feb 2026 → Feb 2027 expected | periprosthetic joint infection | University of Miami | Recruiting | No outcome recorded |
| Phase 1 | NCT05753878 Background | Nov 2022 → Jan 2023 | COVID-19 | Huahui Health | Completed | No outcome recorded |
| Phase 1 | NCT03200808 Background | Oct 2013 → Oct 2018 | vulvar disease | Maternal and Child Health Hospital of Hubei Province | Completed | No outcome recorded |
| Phase 1 | NCT00159510 Comparator | Apr 2004 → Sep 2014 | infectious disease with sepsis | Northern State Medical University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05092165 Comparator | Oct 2021 → Dec 2025 | acute kidney injury | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 2 | NCT04110418 Comparator | Feb 2019 → Feb 2020 | neonatal sepsis | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT02295774 Comparator | Feb 2013 → Dec 2014 | colorectal cancer | Cosmo Technologies Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01407887 Comparator | Aug 2011 | Plasmodium falciparum malaria | Heidelberg University | Completed | No outcome recorded |
| Phase 2 | NCT03287219 Comparator | May 2011 → Jan 2012 | — | Cosmo Technologies Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01276054 Background | Dec 2010 → Oct 2011 | female breast carcinoma, lymphedema | University of Southern California | Terminated | No outcome recorded |
| Phase 2 | NCT00684944 Comparator | Sep 2007 → Dec 2010 | Alzheimer disease | TauRx Therapeutics Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00515333 Comparator | Aug 2004 → Dec 2007 | Alzheimer disease | TauRx Therapeutics Ltd | Completed | No outcome recorded |
| Phase 2/3 | NCT06005558 Comparator | Aug 2023 → Apr 2024 | infectious disease with sepsis | National Cancer Institute, Egypt | Completed | No outcome recorded |
| Phase 2/3 | NCT07067814 Comparator | Jun 2023 → Feb 2025 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01694966 Comparator | Sep 2013 → Oct 2016 | colorectal cancer | Cosmo Technologies Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01847612 Comparator | Jul 2013 → Jul 2025 | liver disorder | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 4 | NCT04054999 Comparator | Nov 2019 → Feb 2023 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT02910765 Comparator | Oct 2016 → Mar 2017 | infectious disease with sepsis | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT01386879 Background | Jul 2011 → Oct 2012 | — | Thomas Jefferson University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT06731881 Background | Jun 2025 → Jun 2026 overdue | nasal disorder | Guy's and St Thomas' NHS Foundation Trust | Recruiting | No outcome recorded |
| — | NCT01725477 Background | Sep 2012 → Feb 2014 | fallopian tube disorder | Pourmatroud, Elham, M.D. | Completed | No outcome recorded |
| — | NCT01539135 Background | Apr 2012 → May 2013 | lung disorder | Medtronic - MITG | Completed | No outcome recorded |
| — | NCT02303886 Comparator | Mar 2009 → Jun 2012 | neuropathy, painful | Uppsala University | Completed | No outcome recorded |
| — | NCT00486174 Comparator | Jun 2007 → ? | infectious disease with sepsis | Queen's University | Withdrawn | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2022-09-20 | Ondine Biomedical Inc. | Results Photodisinfection successfully eradicates pathogens associated with replacement joint infections ondinebio.com ↗
A research team in Zurich, Switzerland has presented results from an in vitro study showing that photodisinfection achieved >99.99% eradication (4-7 log 10 kill) of the key pathogens in biofilms associated with implantable joint infections, with no reported regrowth. |
| 2022-04-05 | Ondine Biomedical Inc. | Results Photodisinfection effective against SARS-CoV-2 ondinebio.com ↗
Our results show that photodisinfection with methylene blue is highly effective against in vitro isolates of SARS-CoV-2. |
| 2015-01-05 | Daiichi Sankyo | Regulatory Daiichi Sankyo Receives Approval in Japan for the Manufacture and Marketing of Methemoglobinemia Treatment Methylene Blue Injection 50 mg daiichisankyo.com ↗
Daiichi Sankyo Receives Approval in Japan for the Manufacture and Marketing of Methemoglobinemia Treatment Methylene Blue Injection 50 mg |
| 2014-03-17 | Daiichi Sankyo | Regulatory Daiichi Sankyo Files NDA in Japan for Methaemoglobinaemia Injection Methylene Blue daiichisankyo.com ↗
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has filed an NDA for the manufacture and marketing in Japan of the methaemoglobinaemia injection Methylene Blue ( INN: Methylthioninium chloride). |
All press releases naming this drug 7 releases
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 107 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Methylene Blue | “Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine...” NCT05894954 ↗99“A saturated swab containing 0.01% methylene blue and 0.25% chlorhexidine gluconate will be applied to nares, which is then activated by light.” NCT06731881 ↗ “Methylene Blue 1 mg/kg water solution. Participants will orally receive Methylene Blue solution of 1 mg/kg concentration one time if any.” NCT05003492 ↗ “Application of NF-031 solution (methylene blue 0.01% USP (methylthioninium chloride) and 0.25% chlorhexidine gluconate) in the nares” NCT06702878 ↗ “A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.” NCT05753878 ↗ “The tooth extraction sockets were filled with photosensitizer methylene blue.” NCT05664087 ↗ |
| Known as | Basic blue 9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | Basic blue 9 trihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | C.I. 52015 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | C.i. basic blue 9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | C.i. basic blue 9 trihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | Chlorure de methylthioninium | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | Cloruro de metiltioninio | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | Dndi1417128 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | Investigational Product: Methylene Blue MMX modified release tablets | “Investigational Product: Methylene Blue MMX® modified release tablets” NCT01694966 ↗ |
| Known as | Lowacryl blue 9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | Lumeblue (previously known as methylthioninium chloride cosmo) | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | MB-MMX | “When combined with a pH- and time-dependent multimatrix structure, a per-oral methylene blue formulation (MB-MMX) can be delivered directly to the colorectal mucosa.” PMID 30742834 ↗ Feb 20191“An oral formulation of methylene blue with colonic delivery (MB-MMX) has been developed to increase detection of colorectal polys during colonoscopy.” PMID 29906809 ↗ Jun 2018 |
| Known as | MBD | “methylene blue dye (MBD)” PMID 19846959 ↗ Oct 2009 |
| Known as | metheylne blue | “metheylne blue with normal saline” NCT01725477 ↗ |
| Known as | methylen blue | “Drug: methylen blue &normal saline” NCT01725477 ↗ |
| Known as | METHYLENE BLUE ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | methylene blue dye | “methylene blue dye (MBD)” PMID 19846959 ↗ Oct 2009 |
| Known as | Methylene Blue MMX | “Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.” NCT03287219 ↗2“To evaluate the effect of oral 200 mg Methylene Blue MMX® tablets” NCT02295774 ↗ “Oral dose, 8 Methylene Blue MMX® tablets over a 4hr schedule” NCT01694966 ↗ |
| Known as | Methylene Blue Oral Product | “Drug: Methylene Blue Oral Product” NCT03262077 ↗ |
| Known as | Methylene blue trihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | Methylenium ceruleum | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | methylthioninium chloride | “Participants in the experimental sample received methylthioninium chloride, Methylene Blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) orally in...” NCT04933864 ↗2“Application of NF-031 solution (methylene blue 0.01% USP (methylthioninium chloride) and 0.25% chlorhexidine gluconate) in the nares” NCT06702878 ↗ |
| Known as | Methylthioninium chloride proveblue | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | NSC-215213 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | NSC-617593 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | NSC-759135 | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | Provayblue | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Known as | PROVAYBLUETM | “Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes” NCT04054999 ↗ |
| Known as | TRx0014 | “Drug: TRx0014” NCT00515333 ↗ |
| Known as | Urolene blue | ChEMBL registry synonym — accepted as the source's own label CHEMBL191083 ↗ |
| Action | Inhibit | “methylene blue (MB), an inhibitor of NO pathway” NCT00159510 ↗ |
| Modality | Diagnostic / imaging agent | “using isotope and methylene blue dye injection to localize precisely Sentinel Lymph Node (SLN)” NCT00314405 ↗ |
| Route | Other | “MB will be injected as a bolus” NCT00159510 ↗ |